CIRG
 |
|
|
 |
CIRG at ASCO 2007
Dr Mark Pegram presented the "BCIRG 007 First overall survival analysis of a multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first line chemotherapy for patients with metastatic breast cancer containing the Her2/neu alteration" on Sunday 3, 2007.
CIRG was present with 2 posters at ASCO this year:
"BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer"
Presented by Dr Valero at the poster discussion on MBC Abstract#1020
"BCIRG 001 Molecular Analysis: Identification of prognostic factors in patients (pts) receiving adjuvant therapy for node-positive (N+) breast cancer (BC)"
Presented by Dr Mackey on behalf of Dr Dumontet at the poster discussion in the adjuvant BC setting abstract #520
In order to view any of the above downloadable PDF files you will require the free Adobe Acrobat Reader.
